AKT1 and neoplasm: Moreover, treatment of ErbB2-driven mouse mammary tumors with ErbB2 neutralizing antibodies together with v-akt murine thymoma viral oncogene homolog 1 (AKT) inhibitors results in increased CTL infiltration and delayed tumor outgrowth (Wang et al., 2012).